|
Bengaluru, India, June 28, 2018
“This is in reference to the announcement by our global partner, Mylan, of a commercialization agreement with Lupin for biosimilar Etanercept for certain markets. Biocon clarifies that it retains its economic interest in this arrangement vis-à-vis Mylan in accordance with its existing collaboration agreement and would benefit from the opportunity to accelerate commercialization of this product.” -Company Spokesperson
|
